Phase II study of carboplatin followed by sequential gemcitabine and paclitaxel as first-line treatment for advanced ovarian cancer

International Journal of Gynecological Cancer

Volumn 17, Issue 2, 2007, Pages 350-358

  Friedlander, M ^a   Buck, M ^b   Wyld, D ^c   Findlay, M ^d   Fitzharris, B ^e   De Souza, P ^f   Davies, T ^g   Kalimi, G ^h   Allan, S ⁱ   Perez, D ^j   Harnett, P ^k  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^d WELLINGTON HOSPITAL   (New Zealand)

^e CHRISTCHURCH HOSPITAL   (New Zealand)

^f ST GEORGE HOSPITAL   (Australia)

^g ELI LILLY AUSTRALIA PTY LTD   (Australia)

^h ELI LILLY AND COMPANY   (United States)

ⁱ PALMERSTON NORTH HOSPITAL   (New Zealand)

^j DUNEDIN HOSPITAL   (New Zealand)

^k WESTMEAD HOSPITAL   (Australia)

more..

Author keywords

Carboplatin; Gemcitabine; Ovarian cancer; Paclitaxel; Sequential

Indexed keywords

ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTIEMETIC AGENT; CA 125 ANTIGEN; CARBOPLATIN; DEXAMETHASONE; GEMCITABINE; GROWTH FACTOR; PACLITAXEL; PROMETHAZINE; RANITIDINE; TUMOR MARKER;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURGERY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHRONOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; CYTOREDUCTIVE SURGERY; DISEASE MARKER; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; HYPOALBUMINEMIA; LEUKOPENIA; LIVER FUNCTION; MOTOR NEUROPATHY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVARY CANCER; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR BIOPSY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA; DEOXYCYTIDINE; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; OVARIAN NEOPLASMS; PACLITAXEL; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33947258908     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2007.00795.x     Document Type: Article

References (29)

1. Australian Institute of Health and Welfare (AIHW) and Australian Association of Cancer Registries (AACR). Cancer in Australia 2000. AIHW Cat No. CAN18 (Cancer Series No. 23). Canberra, Australia: AIHW, 2003.
2. Poveda A. Ovarian cancer: is the news good enough?. Int J Gynecol Cancer 2005;15 (Suppl. 3):298-306.
3. Ozols RF. Treatment goals in ovarian cancer. Int J Gynecol Cancer 2005;15(Suppl. 1):3-11.
4. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
5. Piccart MJ, Bertelsen K, James K et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000;92:699-708.
6. Ozols RF, Bundy BN, Greer BE et al. Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;2:3194-200.
7. ICON Collaborators. ICON2: randomized trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. International Collaborative Ovarian Neoplasm Study. Lancet 1998;352:1571-6.
8. International Collaborative Ovarian Neoplasm Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 2002;360:505-15.
9. Lambert HE, Rustin GJ, Gregory WM, Nelstrop AE. A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group Study. Ann Oncol 1997;8:327-33.
10. Bertelsen K, Jakobsen A, Stroyer J et al. A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA). Gynecol Oncol 1993;49:30-6.
11. Wahl AF, Donaldson KL, Fairchild C et al. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med 1996;2:72-9.
12. Lund B, Hansen OP, Theilade K, Hansen M, Neijt JP. Phase II study of gemcitabine (2′, 2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 1994;86:1530-3.
13. Shapiro JD, Millward MJ, Rischin D et al. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol 1996;63:89-93.
14. Friedlander M, Millward MJ, Bell D et al. A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. Ann Oncol 1998;9:1343-5.
15. von Minckwitz G, Bauknecht T, Visseren-Grul CM, Neijt JP. Phase II study of gemcitabine in ovarian cancer. Ann Oncol 1999;10:853-5.
16. Hansen SW, Anderson H, Boman K et al. Gemcitabine, Carboplatin, Paclitaxel (GCP) as first-line treatment of ovarian cancer FIGO stages IIB-IV. Proc Am Soc Clin Oncol 1999;18:357a. Abstract 1379.
17. Geertsen P, Hansen M, Stroyer I, Hansen SW. Combination chemotherapy with platinum, paclitaxel, and gemcitabine in patients with relapsed ovarian carcinoma. Proc Am Soc Clin Oncol 1999;18:361a. Abstract 1395.
18. Rustin GJ, Nelstrop AE, McClean P, Brady MF, McGuire WP, Hoskins WJ. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA-125. J Clin Oncol 1996;14:1545-51.
19. Rustin GJS, Nelstrop AE, Bentzen SM, Bond SJ, McClean P. Selection of active drugs for ovarian cancer based on CA-125 and standard response rates in phase II trials. J Clin Oncol 2000;18:1733-9.
20. Bookman MA. Standard treatment in advanced ovarian cancer in 2005: the state of the art. Int J Gynecol Cancer 2005;15(Suppl. 3):212-20.
21. Hansen SW. Gemcitabine, platinum, and paclitaxel regimens in patients with advanced ovarian carcinoma. Semin Oncol 2002;29(1 Suppl. 1):17-9.
22. Micha JP, Goldstein BH, Rettenmaier MA et al. Pilot study of outpatient paclitaxel, carboplatin and gemcitabine for advanced stage epithelial ovarian, peritoneal, and fallopian tube cancer. Gynecol Oncol 2004;94:719-24.
23. Duffy MJ, Bonfrer JM, Kulpa J et al. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. Int J Gynecol Cancer 2005;15:679-91.
24. Bridgewater JA, Nelstrop AE, Rustin GJ, Gore ME, McGuire WP, Hoskins WJ. Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel. J Clin Oncol 1999;17:501-8.
25. Harries M, Moss C, Perren T et al. A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer. Br J Cancer 2004;91:627- 32.
26. Vasey PA, Atkinson R, Osborne R, Parkin D, Symonds R, Paul J. SCOTROC 2A: carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer. Br J Cancer 2006;94:62-8.
27. Bookman MA. Developmental chemotherapy in advanced ovarian cancer: incorporation of newer cytotoxic agents in a phase III randomized trial of the Gynecologic Oncology Group (GOG-0182). Semin Oncol 2002;29(1 Suppl. 1):20-31.
28. Bookman MA; for the Gynecologic Cancer InterGroup (GCIG). GOG0182-ICON5: 5-arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG-lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma [abstract]. J Clin Oncol 2006 (ASCO Annual Meeting Proceedings) Part I. 2006;24:18S:256s. Abstract 5002.
29. du Bois A, Belau A, Wagner U et al. for the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGOOVAR). A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC-IV (AGO-OVAR protocol OVAR-8). Gynecol Oncol 2005;96:444-51.